genprowebdirectory
GEN Edge
News
Insights
Trends for 2021
Trends for 2020
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Get GEN Edge
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
GEN Edge
Synthetic Biology
Flush with Cash, Foresite Aims to Live Up to Its Name
OMICs
From Genomes to Drugs: An Interview with Vertex CSO David Altshuler
Gene Therapy
AI Gets Gene Therapy Over the Immunity Hump
Coronavirus
Immunai Expands from Observational to Functional Genomics
Antibody Drug Conjugates
RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision
News
Drug Discovery
ICON to Acquire PRA for $12B, as COVID-19 Spurs CRO Consolidation
Artificial Intelligence
AI Joins Forces with fMRI to Decode Brain Dynamics Underlying Neurofeedback
Neuroscience
First Compound That Potentially Halts Degeneration of Neurons in ALS Identified
Aging
Scientists Identify Mechanism Linking Exercise with Bone Strength and Immunity
Biomarkers
Genetic Method Improves Estimating Prostate Cancer Risk in Multi-Ethnic Groups
Insights
All
Trends for 2021
Trends for 2020
A-Lists
Top 7 Best Selling COVID-19 Vaccines and Drugs of 2020
Bioprocessing
COVID-19 Increasing Risk of Cyberattacks for Digital Biopharma
Bioprocessing
Case Study: How to Accelerate COVID-19 Vaccine Development
Bioprocessing
Flexibility is Key to Advances in Biomanufacturing
A-Lists
A-Lists
Top 7 Best Selling COVID-19 Vaccines and Drugs of 2020
January 2021 Vol. 41 No. 1
Seven Biopharma Trends to Watch in 2021
A-Lists
Top 15 Best-Selling Drugs Launched in 2020
A-Lists
Top 50 NIH-Funded Institutions of 2020
July 2020 Vol. 40 No. 7
Top 10 Earners among Women Biopharma Executives
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Synthetic Biology
Flush with Cash, Foresite Aims to Live Up to Its Name
Drug Discovery
ICON to Acquire PRA for $12B, as COVID-19 Spurs CRO Consolidation
Biomarkers
Genetic Method Improves Estimating Prostate Cancer Risk in Multi-Ethnic Groups
Cancer
Blocking a Treg Mechanism Can Scorch Tumors without Stoking Autoimmunity
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Home
Zinc Finger Nucleases
Zinc Finger Nucleases
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Zinc Finger Nucleases
Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’
Zinc Finger Nucleases
Novartis Taps Sangamo Zinc Finger Tech for Gene Regulation Therapies
Zinc Finger Nucleases
From Alzheimer’s to Zinc Fingers
Zinc Finger Nucleases
Sangamo Researchers Show Improvements to Zinc Finger Nuclease Technology
Zinc Finger Nucleases
Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition
Zinc Finger Nucleases
Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership
Zinc Finger Nucleases
Sangamo, Pfizer Partner on Gene Therapy for ALS, FTLD
Zinc Finger Nucleases
Sangamo Genome Editing Trial, Assessing MPS II Candidate, Treats First Patient
Zinc Finger Nucleases
Genetically Engineered Pigs May Fly as Cancer Models
Zinc Finger Nucleases
A Tap of Radiation Enhances Gene Editing of Human Stem Cells
Zinc Finger Nucleases
Gene Editing Technique Boosts Patients’ HIV Resistance
Zinc Finger Nucleases
Genetic Bug Spray? Scientists Alter Mosquitoes’ Sense of Smell
Zinc Finger Nucleases
Sigma Divisions Establish Screening Technology Deals
Zinc Finger Nucleases
Turning on Genes with The Blues
Zinc Finger Nucleases
Synthetic Biology Expands Beyond Bacteria
Load more
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
/* The alert message box */ .alert { padding: 20px; background-color: #ff9800; /* Red */ color: white; margin-bottom: 15px; } /* The close button */ .closebtn { margin-left: 15px; color: white; font-weight: bold; float: right; font-size: 22px; line-height: 20px; cursor: pointer; transition: 0.3s; } /* When moving the mouse over the close button */ .closebtn:hover { color: black; } .td_module_flex_2 .entry-title { font-size: 17px; line-height: 20px; }
![Sangamo Therapeutics aims to position itself as a leader in the development of chimeric antigen receptor-modified regulatory T-cell (CAR-Treg) cell therapies for immunological diseases with its planned acquisition of TxCell. [Source: TxCell]](https://www.genengnews.com/wp-content/uploads/2018/08/ENTrIA_recognition_EN_without_entria1024x9291472362223-265x198.png "Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition")
